Form 4: Calidi Biotherapeutics Director Schoeneck Receives Stock Grant

Director James A. Schoeneck of Calidi Biotherapeutics, Inc. reports acquisition of 79,687 shares of common stock through a restricted stock unit (RSU) grant.

Summary

• James A. Schoeneck, a director at Calidi Biotherapeutics, Inc., acquired 79,687 shares of common stock on June 28, 2024.
• The acquisition was in the form of restricted stock units (RSUs) granted under the company's 2023 Equity Incentive Plan.
• The RSUs vested fully on the grant date, with each RSU representing the right to receive one share of Calidi Biotherapeutics' common stock.
• Following the transaction, Schoeneck directly owns 1,071,781 shares of Calidi Biotherapeutics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock grant) and doesn't contain any overtly positive or negative information. It's a neutral event from an investment perspective.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.
• Immediate vesting of the RSUs could incentivize the director to contribute to the company's success.

Industry Context

Stock grants to directors are a common practice in publicly traded companies to align their interests with those of shareholders and incentivize performance.

Stakeholder Impact

• The stock grant could have a minor dilutive effect on existing shareholders.

Key Dates